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Monocyte-derived cells, constituents of the cancer microenvironment, support chronic lymphocytic leukemia
(CLL) cell survival in vitro via direct cell-cell interaction and secreted factors. We hypothesized that
circulating absolute monocyte count (AMC) reflects the monocyte-derived cells in the microenvironment,
and that higher AMC is associated with increased CLL cell survival in vivo and thus inferior CLL patient
outcomes. We assessed the extent to which AMC at diagnosis of CLL is correlated with clinical outcomes,
and whether this information adds to currently used prognostic markers. We evaluated AMC, clinically used
prognostic markers, and time to event data from 1,168 CLL patients followed at the Mayo Clinic, the Duke
University Medical Center, and the Durham VA Medical Center. Elevated AMC was significantly associated
with inferior clinical outcomes, including time to first therapy (TTT) and overall survival (OS). AMC combined
with established clinical and molecular prognostic markers significantly improved risk-stratification of CLL
patients for TTT. As an elevated AMC at diagnosis is associated with accelerated disease progression, and
monocyte-derived cells in the CLL microenvironment promote CLL cell survival and proliferation, these
findings suggest that monocytes and monocyte-derived cells are rational therapeutic targets in CLL.
Am. J. Hematol. 91:687–691, 2016. VC 2016 Wiley Periodicals, Inc.
 Introduction
An altered tumor microenvironment is recognized as a hallmark of cancer [1]. In chronic lymphocytic leukemia (CLL), an incurable malignancy
with a spectrum of clinical aggressiveness, numerous laboratory-based studies have supported the concept that mononuclear phagocytes (mono-
cytes and macrophages), derived from inflammatory peripheral blood monocytes or tissue resident macrophages [2], in the tumor microenviron-
ment modulate CLL cell viability, survival, and resistance to drug-induced apoptosis [3–6]. These data suggest that circulating monocytes may
contribute to the population of CLL-associated macrophages in lymph nodes, spleen, and bone marrow. Elevated level of circulating monocytes
could promote CLL cell survival and proliferation, conferring worse clinical outcomes for CLL patients.
In various solid and hematologic malignancies, the circulating absolute monocyte count (AMC) at the time of diagnosis has prognostic signifi-
cance [7–13]. In CLL, such work has not fully evaluated the relevance of AMC with other routinely used prognostic markers in the context of
large patient cohorts. Thus, it is currently unclear the extent to which AMC adds information to other routinely measured markers in CLL, and
whether it should be used by clinicians.
To assess the extent to which AMC is an in vivo reflection the in vitro protective effect of monocyte-derived cells in the CLL microenviron-
ment, we reviewed AMC values at the time of CLL diagnosis, using retrospective data from two large CLL cohorts at the Mayo Clinic and the
Duke University and Durham VA Medical Centers. We sought to determine the prognostic significance of AMC at diagnosis in terms of overall
survival (OS) and time to first therapy (TTT) in CLL, as well as to evaluate AMC together with other prognostic markers.
 Methods
Patients. Patients with a diagnosis of CLL [14], either evaluated at the Mayo Clinic Rochester, the Duke University Medical Center, or the Durham VA Medical Center,
were enrolled in IRB approved protocols at their respective institutions to collect clinical data. Data obtained included date of diagnosis, Rai stage, treatment history, gender,
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age, and molecular prognostic factors, specifically immunoglobulin heavy chain
variable region (IGHV) gene mutation status, ZAP70 status (>20% considered pos-
itive), CD38 status (>30% considered positive), and cytogenetic aberrations by
interphase fluorescence in situ hybridization (FISH) testing.
The AMC was defined as the monocyte count measured on the day of diagnosis
63 months, prior to the administration of any CLL-directed therapy. CLL patients
in whom AMC values were not available were not included in this analysis. The
monocyte count was determined either via automated or manual differential.
Statistical considerations. The primary outcome was TTT, which was defined as
time from date of CLL diagnosis to date of first therapy or date of last follow-up if
untreated. Prognostic analyses were conducted using Cox proportional hazards mod-
els [15]. The resulting hazard ratios (HR), 95% confidence intervals (CI), and P val-
ues are reported. These analyses were adjusted for age (log10 transformed), gender,
and Rai stage, which was categorized as 0, 1, or 2, and 3 or 4, and were stratified by
site between the Mayo Clinic and Duke University/Durham VA Medical Centers.
Analyses were based on all available patients with complete baseline data. Missing-
ness of baseline covariates was considered noninformative. AMC was treated as a
continuous variable, while CD38, ZAP70, IGHV and FISH statuses were treated as
binary variables (reference values were CD38-, ZAP70-, IGHV mutated, and FISH
negative for 17p and 11q deletions, respectively). We used multivariate Cox propor-
tional hazards models to test for interactions between AMC and other prognostic
markers in models adjusted for age, gender and Rai stage and stratified by site.
To determine if AMC added information to other routinely measured markers, we
used analysis of deviance [15] to compare multivariate Cox proportional hazards mod-
els. A model including AMC and CD38, ZAP70, IGHV, and FISH statuses was com-
pared to a nested model lacking AMC as a predictor. Both models were adjusted for
age, gender and Rai stage and stratified by site. As an illustration of the contribution
of AMC, HR, 95% CI and P values are reported for all predictors in the full model.
These time to event analyses were also used applied to the secondary outcome of OS,
defined as time from date of CLL diagnosis to death date or date of last follow-up.
Conditional inference trees [16] were used in a TTT model with AMC (but
without other covariates) stratified by site, to determine the AMC value of maxi-
mum separation of TTT, defining “high” or “low” AMC. This cut-off value was
used to visualize the association of AMC and the time to event outcomes in
Kaplan–Meier (KM) [15] plots of TTT and OS. This analysis was used for visual-
ization only, rather than model-building purposes. For consistency, the same cut-
off value was used for both the TTT and OS KM plots. To illustrate the use of
AMC in concert with other routinely measured markers in risk stratification of
patients, KM plots of TTT were generated with separate curves for each combina-
tion of dichotomized AMC and selected risk factors.
Statistical analyses were conducted at the Duke Cancer Institute. We used the R
software environment for statistical computing and graphics [17] and the survival
[18], party [19], and coin [20] extension packages to conduct the statistical analyses
and to generate the figures. P values and confidence interval estimates were not
adjusted for multiple testing.
 Results
CLL patient characteristics
We evaluated data collected from CLL patients at the Mayo Clinic
(Mayo; n5 947) and the Duke University and Durham VA Medical
Centers (Duke/VA; n5 221). Demographic, clinical, and molecular
prognostic factors from both cohorts are outlined in Table I. The Mayo
Clinic cohort patients were older at the time of diagnosis, included
more women, and had a lower fraction of patients with unfavorable
risk prognostic factors. The combined dataset (n5 1,168) included
patients with high-risk prognostic features such as Rai stage of 3 or 4
(6%), unmutated IGHV (26%), and unfavorable interphase cytogenetics
(17pdel or 11qdel by FISH; 9%). We analyzed the combined dataset to
evaluate associations between AMC at diagnosis and clinical outcomes.






(n5 1168) P value
Age at diagnosis (in years),
median (range)
65 (25–97) 62 (30–90) 64.5 (25–97) 0.0002
Gender (%) 0.0083
Female 327 (35) 55 (25) 382 (33)
Male 620 (65) 164 (74) 784 (67)
NA 0 (0) 2 (1) 2 (0)
Rai stage at diagnosis (%) 0.6412
0 481 (51) 122 (55) 603 (52)
1 or 2 410 (43) 77 (35) 487 (42)
3 or 4 50 (5) 18 (8) 68 (6)
NA 6 (1) 4 (2) 10 (1)
CD38 (%) 0.0229
Neg 602 (64) 168 (76) 770 (66)
Pos 261 (28) 48 (22) 309 (26)
NA 84 (9) 5 (2) 89 (8)
ZAP70 (%) 0.0002
Neg 417 (44) 105 (48) 522 (45)
Pos 197 (21) 93 (42) 290 (25)
NA 333 (35) 23 (10) 356 (30)
IGHV (%) 0.1043
Mutated 284 (30) 121 (55) 405 (35)
Unmutated 226 (24) 72 (33) 298 (26)
NA 437 (46) 28 (13) 465 (40)
FISH (%) 0.0585
Favorable 460 (49) 135 (61) 595 (51)
Unfavorable 69 (7) 32 (14) 101 (9)
NA 418 (44) 54 (24) 472 (40)
Time to therapy (in years),
median (range)
6.28 (0–10.30) 5.95 (0–18.47) 6.17 (0–18.47) 0.8921
Patients who required therapy (%) 235 (25) 109 (49) 344 (29)
Overall survival (in years),
median (range)
9.35 (0–10.31) 11.79 (1.16–23.83) 10.54 (0–23.83) <0.0001
Patients who died (%) 184 (19) 75 (34) 259 (22)
Time to follow-up or death (in years),
median (range)
3.77 (0–10.31) 8.68 (1.16–23.83) 4.57 (0–23.83) <0.0001
FISH unfavorable5presence of 17pdel or 11qdel. FISH favorable5 absence of 17pdel and 11qdel. NA5not available.
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Elevated AMC at diagnosis is associated with inferior
clinical outcomes
The AMC at diagnosis ranged from 0 to 23.72 3 103 cells/mm3
(median 0.55) in the Mayo cohort, and 0 to 7.63 3 103 cells/mm3
(median 0.64) in the Duke/VA cohort (P value5 0.0007). In the com-
bined dataset, AMC values ranged from 0 to 23.72 3 103 cells/mm3
(median 0.58). Controlling for age, gender, and Rai stage at diagnosis,
elevated AMC evaluated as a continuous variable was significantly
associated with a shorter time to first therapy (HR 1.13, 95% CI
1.08–1.19, P value< 0.0001). In addition, elevated AMC was signifi-
cantly associated with inferior overall survival (HR 1.09, 95% CI
1.01–1.16, P value5 0.0240). The results of the individual and com-
bined analyses, stratified by site, are shown in Table II.
To graphically visualize and assess the clinical impact of AMC, we
used conditional inference tree analysis that identified 1.545 3 103
cells/mm3 (94th percentile across all patients in the combined dataset)
as an AMC cut-off of maximum separation between prognostic sub-
groups for TTT. Patients with an AMC equal to or above this level at
diagnosis had a shorter time to therapy (HR 2.94, 95% CI 2.13–4.06,
P value< 0.0001), after controlling for age, gender, and Rai stage and
stratifying by site. This cutoff also identified patients with an inferior
overall survival (HR 1.75, 95% CI 1.14–2.67, P value5 0.0104). These
results are shown in Table II and Figure 1. Both as a continuous vari-
able and when considered as a dichotomous variable, elevated AMC
at diagnosis was associated with inferior patient outcomes.
Elevated AMC provides added risk-stratification when
combined with routinely used clinical and molecular
prognostic factors
As seen in Table II, commonly used molecular prognostic markers
(CD38 expression, IGHV mutation status, and interphase cytogenetics
by FISH) were prognostic for TTT and OS in the combined cohort,
after controlling for Rai stage, age, and gender, and cohort. We eval-
uated the contribution of multiple clinical and molecular markers for
their prognostic significance, using a multivariate Cox proportional
hazards model. AMC, as a continuous measure, retained prognostic
significance for TTT within this context (Table III). In addition, using
analysis of deviance to compare this full model to a reduced model
without AMC demonstrated a significant difference between the mod-
els (P5 0.0005), indicating that AMC contributes prognostic informa-
tion about TTT in these cohorts, beyond that contributed by other
currently used prognostic factors. However, AMC was not signifi-
cantly associated with OS in a similar multivariate model.
As shown above, patients with AMC greater than or equal to 1.545
3 103 cells/mm3 at diagnosis comprise a high-risk group (Fig. 1). We
found no significant interactions between AMC and any of the estab-
lished prognostic markers (data not shown). Elevated AMC appeared
to further risk-stratify patient groups defined by clinically used
molecular prognostic markers (Fig. 1). For example, CLL patients
with low AMC and mutated IGHV appeared to have the best progno-
sis, while patients with high AMC/mutated IGHV have a similar
prognosis to patients with low AMC/unmutated IGHV. Similarly,
patients with low AMC and low-risk cytogenetics (absence of 17p or
11q deletions) appeared to have prognoses superior to those of
patients with high AMC and presence of high-risk cytogenetics. A
similar pattern was observed for CD38 and ZAP70 expression (data
not shown). These results suggest that when combined with other
prognostic markers, a high AMC identifies CLL patients at risk for
rapid progression and need for treatment.
 Discussion
This study defines the AMC as a robust prognostic factor in
newly diagnosed CLL. From the perspective of prognostication and
risk-stratification, we note that AMC at diagnosis is an easily meas-
ured marker, has prognostic significance across two cohorts repre-
senting three medical centers, and defines high and low risk groups
of CLL patients even within the context of other commonly used
prognostic markers (such as interphase cytogenetics and IGHV
mutation status). Higher AMC at diagnosis is associated with infe-
rior clinical outcomes, specifically time to first therapy and overall
survival. A similar association has been observed in two smaller
CLL cohorts [12,13].
The findings presented here suggest that circulating blood mono-
cytes reflect the lymph node and bone marrow microenvironment.
Supportive macrophages or nurse-like cells have been established as
important constituents of this microenvironment, favoring CLL cell
viability and providing protection from numerous CLL directed thera-
pies [3,5,6,21]. In other malignancies, an elevated AMC is associated
with higher density of tumor associated macrophages [8]. Thus, in
CLL, a higher AMC could reflect a higher level of monocytes and
macrophages in the tumor microenvironment, which as a protective
feature for CLL cells would confer inferior outcomes for patients.
TABLE II. Univariate Analysis of Absolute Monocyte Count (AMC) as a Continuous Variable, AMC as a Dichotomized Variable (Dichotomized at 1.545 3 103
cells/mm3), and Established Molecular Prognostic Markers, After Controlling for Age, Gender, and Rai Stage at Diagnosis
Mayo Clinic Duke/Durham VA Combined Cohort (stratified by site)
n (events) HR 95% CI P value n (events) HR 95% CI P value n (events) HR 95% CI P value
Time to therapy
AMC (continuous) 941 (232) 1.12 1.06–1.18 <0.0001 215 (107) 1.36 1.09–1.70 0.0059 1156 (339) 1.13 1.08–1.19 <0.0001
AMC (dichotomized) 941 (232) 3.67 2.48–5.44 <0.0001 215 (107) 1.92 1.09–3.37 0.0246 1156 (339) 2.94 2.13–4.06 <0.0001
CD38 1 858 (214) 1.88 1.42–2.48 <0.0001 210 (103) 1.33 0.85–2.09 0.2171 1068 (317) 1.71 1.36–2.16 <0.0001
ZAP70 1 612 (139) 1.29 0.92–1.81 0.1446 192 (88) 1.30 0.85–1.99 0.2336 804 (227) 1.29 0.99–1.69 0.0584
IGHV UM 509 (138) 2.43 1.69–3.50 <0.0001 189 (98) 2.87 1.87–4.41 <0.0001 698 (236) 2.60 1.97–3.42 <0.0001
FISH unfavorable 526 (135) 2.01 1.32–3.07 0.0012 165 (81) 1.46 0.87–2.43 0.1509 691 (216) 1.84 1.33–2.55 0.0002
Overall survival
AMC (continuous) 941 (181) 1.08 1.00–1.16 0.0550 215 (74) 1.14 0.85–1.52 0.3784 1156 (255) 1.09 1.01–1.16 0.0240
AMC (dichotomized) 941 (181) 1.82 1.10–3.02 0.0206 215 (74) 1.50 0.67–3.33 0.3225 1156 (255) 1.75 1.14–2.67 0.0104
CD38 1 858 (157) 1.58 1.14–2.18 0.0062 210 (72) 1.18 0.69–2.02 0.5459 1068 (229) 1.49 1.13–1.96 0.0049
ZAP70 1 612 (64) 1.15 0.68–1.94 0.6051 192 (57) 1.59 0.93–2.69 0.0889 804 (121) 1.40 0.97–2.00 0.0688
IGHV UM 509 (62) 2.57 1.50–4.43 0.0007 189 (71) 2.17 1.31–3.58 0.0026 698 (133) 2.32 1.61–3.33 <0.0001
FISH unfavorable 526 (72) 3.08 1.86–5.12 <0.0001 165 (49) 1.81 0.94–3.46 0.0743 691 (121) 2.58 1.74–3.84 <0.0001
UM5unmutated. FISH unfavorable5presence of 17pdel or 11qdel.
Hazard ratio (HR), 95% confidence intervals (CI), and P value provided by site and for the combined cohort (stratified by site), both for time to therapy and
for overall survival.
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Alternatively, it has also been suggested that a subset of the circu-
lating monocytes are myeloid derived suppressor cells (MDSC;
CD141HLAlo/neg) that function to suppress the immune system and
induce tolerance [22]. Thus, an elevated AMC levels may be a surrogate
for an increase in MDSCs, which could allow CLL cells to evade
immune surveillance. In turn, this would be associated with inferior
patient outcomes. In fact, one report identified an association between
elevated MDSC levels and inferior prognosis in CLL [23].
Most recently, it has been found that monocyte expansion occurs
in leukemic El-TCL1 mice, and monocytes appear to be necessary
for the development and progression of CLL in this mouse model
[24,25]. Interestingly, a therapeutic approach to reduce the number of
monocytes delayed the onset of leukemia when El-TCL1 cells were
adoptively transferred to wildtype or CD41 T-cell depleted mice
[25]. These results suggest that monocyte depletion could be an effec-
tive CLL therapy.
Our study includes data from over 1,000 patients, with broad applic-
ability to patients at other medical centers. However, we note several
details that could affect our conclusions. First, there was variability
between the cohorts in this study that, despite the use of stratification
and controlling for certain covariates, could affect the results obtained.
For example, compared to the Duke/VA cohort, the Mayo Clinic cohort
patients had a lower fraction of patients with unfavorable risk prognos-
tic factors such as unmutated IGHV and presence of 17pdel or 11qdel.
Second, results in the two cohorts could be affected by different dura-
tions of follow-up or by missing baseline covariates (which were
assumed to be noninformative for the purposes of these analyses).
Third, selecting this cohort of patients from the entire Mayo Clinic and
Duke/VA patient populations may have introduced confounders that
could alter the prognostic power of AMC or other established prognos-
tic factors. Last, generalizing the dichotomized AMC to other cohorts
may be difficult since the cut-off value of 1.545 3 103 cells/mm3
Figure 1. Elevated AMC, dichotomized at 1.545 3 103 cells/mm3 is associated with inferior time to therapy (A) and overall survival (B) in the combined cohort.
Total number of patients and number of events for each curve as follows: for TTT, the Low AMC curve had 1098 and 299, respectively, and the High AMC
curve had 70 and 45, respectively. For OS, the Low AMC curve had 1098 and 233, respectively, and the High AMC curve had 70 and 26, respectively. Ele-
vated AMC in combination with clinically used molecular prognostic markers, such as IGHV mutational status (C) or chromosomal aberrations measured by
FISH (D), provide additional risk-stratification in terms of time to therapy. UM5unmutated; M5mutated; FISH1 5presence of 17pdel or 11qdel; FISH-
5 absence of 17pdel or 11qdel. In (C), the total number of patients and number of events for each curve are as follows: M and low AMC with 386 and 81,
respectively; M and high AMC with 19 and 12, respectively; UM and low AMC with 266 and 119, respectively; and UM and high AMC with 32 and 26 respec-
tively. In (D), the total number of patients and number of events for each curve are as follows: FISH – and Low AMC with 552 and 114, respectively; FISH2
and high AMC with 43 and 24, respectively; FISH1 and low AMC with 89 and 39, respectively; FISH1 and high AMC with 12 and 11, respectively. [Color figure
can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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represented the 94th percentile, and thus may be easily skewed by varia-
tions in ranges and outliers in AMC between populations. In fact, this
cutoff value is higher than those reported in earlier publications [12,13].
One potential concern about the reproducibility across centers is
related to different methods of measuring AMC, whether it be by
manual or automated differential, or the type of automated blood
count instrument. In the Duke/VA cohort, no differences in AMC
were observed between Duke and the VA even though automated
differentials were consistently used to determine AMC for VA
patients while manual differentials were typically used for Duke
patients (data not shown). In the Mayo clinic cohort, slight but sig-
nificant differences were seen in median AMC determined with
manual or automated methods (0.52 vs. 0.57 3 103 cells/mm3,
P5 0.01). However, in a subset of patients in the Mayo clinic cohort,
the AMC was determined by both manual and automated differen-
tials on the same day. In these patients, no significant differences in
AMC were observed. Importantly, regardless of site (Mayo, Duke, or
Durham VA), AMC at diagnosis remained a strong predictor of clin-
ical outcomes.
Collectively, these findings add to the growing body of evidence
demonstrating that extrinsic factors, particularly those related to the
tumor microenvironment, promote CLL progression and provide val-
uable prognostic information. The AMC is inexpensive, easily inter-
preted, universally available, and identifies patients at high-risk of
disease progression, particularly when used in conjunction with con-
ventional prognostic factors. As monocyte-derived cells promote CLL
progression via cell-cell interactions, secretion of trophic factors, and
suppression of host immunity, the observation that an elevated AMC
is associated with more rapid disease progression may have significant
therapeutic implications.
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AMC 1.18 1.09–1.27 <0.0001
The number of patients with complete data for this analysis5449, and
the number of events5 147. Hazard ratio (HR), 95% confidence intervals
(CI), and P value provided for the combined cohort (stratified by site). Rai
stage is collapsed to three levels (0; 1 or 2; 3 or 4). UM5unmutated. FISH
unfavorable5presence of 17pdel or 11qdel.
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